🇺🇸 SECQuantum Biopharma Ltd.Codex · 实盘不做把握 2/10不做原因:无增量信息
北京时间·🕒 发布 00:39:12·⟳ 抓取 00:39:47 +35s·⚡ 决策 09-09 00:44:46 +4m59s·49.1 天前
Quantum BioPharma 6-K/A 仅为并入既有 FDA 公告，未带来新增信息
这份 6-K/A 仅是把 2026-08-10 已公开的 FDA/IND 新闻稿并入 F-3，文件还明确说明不更新原披露；因此本次没有新增可交易事实。
📄 原文Quantum Biopharma Ltd.↗ 原文
----- qntm6ka090826.htm ----- 6-K/A 1 qntm6ka090826.htm FORM 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Was…
不做 Quantum BioPharma Ltd.（QNTM.US）
仅为 6-K/A 修订并入旧新闻稿，没有新增可交易事实，催化已在 8 月 10 日原公告时释放。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实层面，这是一份纯修订性 SEC 文件，不是新的业务、监管或财务催化。它只是把 8 月 10 日已发布的 Lucid-MS FDA 许可新闻稿纳入注册声明，市场若要定价，也已在原公告时完成。今天没有新的方向性增量，因此不做。
消息传播链
- FDA 许可 Lucid-MS 进入 Phase 2 的核心正面信息在这一天已公开。
- 6-K/A 仅把既有新闻稿并入 F-3，并明确不修改原披露；没有新增事件。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-13 · 影响 invalidates
未命中任何新增监管、财务或临床进展；文件仅为并入引用。
检索:Quantum BioPharma 2026-08-13 6-K/A 是否包含新的 FDA 结果、融资条款或临床更新 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例没有改变结论；这类 filing-only 修订通常不构成新仓位依据。
方向:无可用高相似先例；这是行政修订文件，不是可比交易催化。
涨幅量级:不适用，未做事件收益校准。
形态:不适用。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,007 字
----- qntm6ka090826.htm -----
6-K/A
1
qntm6ka090826.htm
FORM 6-K/A
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE
ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE
ACT OF 1934
For the month of September
2026
Commission File Number: 001-39152
QUANTUM BIOPHARMA LTD.
(Registrant)
1 Adelaide Street East,
Suite 801
Toronto, Ontario M5C
2V9
(Address of Principal
Executive Offices)
Indicate by check mark whether the Registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
This Amendment No. 1
(this “
Amendment No. 1
”) to the report on Form 6-K originally furnished with the U.S. Securities and Exchange Commission
on April 1, 2026, Accession Number 0001171843-26-002144 (the “
Initial Report
”), is being furnished solely to incorporate
Exhibit 99.1 filed as part of the Initial Report into the Registrant’s Registration Statement on Form F-3 (File No.
333-276264
). Except
as set forth herein, there are no other changes to the Initial Report.
1
DOCUMENTS INCORPORATED
BY REFERENCE
Exhibit 99.1 included
with this Amendment No. 1 is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No.
333-276264
)
and shall be deemed to be a part thereof from the date on which the Initial Report was furnished, to the extent not superseded by documents
or reports subsequently filed or furnished.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
QUANTUM BIOPHARMA LTD.
(Registrant)
Date: September 8, 2026
By
/s/ Donal Carroll
Donal Carroll
Chief Financial Officer
3
EXHIBIT INDEX
Exhibit
Description of Exhibit
99.1
Press Release dated April 1, 2026 (incorporated by reference to Exhibit 99.1 to the Form 6-K furnished on April 1, 2026, Accession No. 0001171843-26-002144)
4
6-K/A
1
qntm6ka090826.htm
FORM 6-K/A
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE
ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE
ACT OF 1934
For the month of September
2026
Commission File Number: 001-39152
QUANTUM BIOPHARMA LTD.
(Registrant)
1 Adelaide Street East,
Suite 801
Toronto, Ontario M5C
2V9
(Address of Principal
Executive Offices)
Indicate by check mark whether the Registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
This Amendment No. 1
(this “
Amendment No. 1
”) to the report on Form 6-K originally furnished with the U.S. Securities and Exchange Commission
on April 1, 2026, Accession Number 0001171843-26-002144 (the “
Initial Report
”), is being furnished solely to incorporate
Exhibit 99.1 filed as part of the Initial Report into the Registrant’s Registration Statement on Form F-3 (File No.
333-276264
). Except
as set forth herein, there are no other changes to the Initial Report.
1
DOCUMENTS INCORPORATED
BY REFERENCE
Exhibit 99.1 included
with this Amendment No. 1 is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No.
333-276264
)
and shall be deemed to be a part thereof from the date on which the Initial Report was furnished, to the extent not superseded by documents
or reports subsequently filed or furnished.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
QUANTUM BIOPHARMA LTD.
(Registrant)
Date: September 8, 2026
By
/s/ Donal Carroll
Donal Carroll
Chief Financial Officer
3
EXHIBIT INDEX
Exhibit
Description of Exhibit
99.1
Press Release dated April 1, 2026 (incorporated by reference to Exhibit 99.1 to the Form 6-K furnished on April 1, 2026, Accession No. 0001171843-26-002144)
4
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。